1. Development of Imiquimod-induced HaCaT-THP-1 co-culture for modeling of psoriasis.
- Author
-
Váradi J, Oláh B, Hosszú D, Fenyvesi F, Remenyik J, Homoki J, Nagy B Jr, Fejes Z, Bácskay I, and Klusóczki Á
- Subjects
- Humans, HaCaT Cells, Keratinocytes drug effects, Keratinocytes metabolism, Cytokines metabolism, THP-1 Cells, NF-kappa B metabolism, Cell Proliferation drug effects, Toll-Like Receptor 7 metabolism, Cell Movement drug effects, Models, Biological, Imiquimod, Psoriasis drug therapy, Psoriasis metabolism, Coculture Techniques
- Abstract
Psoriasis is one of the most prevalent and chronic inflammatory disease of the skin, associated with disrupted barrier function. Currently, a widely accepted, generally usable cell culture model has not been developed yet. In the present work, we aimed to establish a co-culture model with human keratinocyte (HaCaT) and human monocyte cells (THP-1) induced by Imiquimod (IMQ), which acts on the TLR7 receptor. The role of TLR7 expressed on THP-1 cells was confirmed by immunofluorescence staining of NF-κB activation. Chloroquine (CH) was used as a receptor inhibitor, in the presence or absence of which the NF-κB pathway was activated. We determined the most effective proliferation-stimulating IMQ concentration by RTCA method and the hyperproliferative effect was investigated by wound-healing test. The effect of IMQ was compared with the effects of the anthocyanin (AC) components from the anti-inflammatory sour cherry extract that we have already studied. We found that IMQ significantly increased the migration rate however, the combined treatment resulted in a decreased migration rate compared to the IMQ treatment alone. Inflammatory cytokines were measured from the supernatant of co-culture by ELISA. During the development of the co-culture intended to model psoriasis, we confirmed the induction effect of IMQ and in the case of AC treatment, we supported the stabilizing effect of the barrier., Competing Interests: Declaration of competing interest We wish to confirm that there is no conflict of interest associated with this publication., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF